Tokyo Tape
Sign in
← CellSeed

Quarterly report · Q3

7776.TEDINET S100PJK7
Period2022-01-01 → 2022-09-30
Filed2022-11-14
StandardJapan GAAP
ConsolidatedNo
Data checks9 of 9 passed
Key figures · 23
MetricValuePeriodScopeSource row
Revenue¥88m2022-01-01 → 2022-09-30StandaloneNet sales
Revenue¥162m2021-01-01 → 2021-12-31StandaloneNet sales (5-year summary)
Operating income−¥564m2022-01-01 → 2022-09-30StandaloneOperating income
Ordinary income−¥571m2022-01-01 → 2022-09-30StandaloneOrdinary income
Ordinary income−¥866m2021-01-01 → 2021-12-31StandaloneOrdinary income loss (5-year summary)
Profit before tax−¥572m2022-01-01 → 2022-09-30StandaloneIncome before income taxes
Net income−¥574m2022-01-01 → 2022-09-30StandaloneProfit loss
Net income−¥913m2021-01-01 → 2021-12-31StandaloneNet income loss (5-year summary)
Total assets¥1.5bnat 2022-09-30StandaloneAssets
Total assets¥1.4bnat 2021-12-31StandaloneAssets
Total liabilities¥401mat 2022-09-30StandaloneLiabilities
Total liabilities¥364mat 2021-12-31StandaloneLiabilities
Net assets / equity¥1.1bnat 2022-09-30StandaloneNet assets
Net assets / equity¥1.0bnat 2021-12-31StandaloneNet assets
Cash and deposits¥941mat 2022-09-30StandaloneCash and deposits
Cash and deposits¥847mat 2021-12-31StandaloneCash and deposits
EPS (basic)¥-28.382022-01-01 → 2022-09-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-9.82022-07-01 → 2022-09-30dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-53.082021-01-01 → 2021-12-31StandaloneBasic earnings loss per share (5-year summary)
Equity ratio71.3%at 2022-09-30StandaloneEquity to asset ratio (5-year summary)
Equity ratio72.4%at 2021-12-31StandaloneEquity to asset ratio (5-year summary)
Shares issued22,159,419at 2022-09-30StandaloneTotal number of issued shares (5-year summary)
Shares issued17,759,419at 2021-12-31StandaloneTotal number of issued shares (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 10
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment profit2022-01-01 → 2022-09-30−¥147m
jpcrp040300-q3r_E24158-000Cell Sheet Regenerative Medicinereportable segmentrevenue2022-01-01 → 2022-09-30¥7m
jpcrp040300-q3r_E24158-000Cell Sheet Regenerative Medicinereportable segmentrevenue external2022-01-01 → 2022-09-30¥7m
jpcrp040300-q3r_E24158-000Cell Sheet Regenerative Medicinereportable segmentsegment profit2022-01-01 → 2022-09-30−¥347m
jpcrp040300-q3r_E24158-000Laboratory Consumable Equipmentreportable segmentrevenue2022-01-01 → 2022-09-30¥81m
jpcrp040300-q3r_E24158-000Laboratory Consumable Equipmentreportable segmentrevenue external2022-01-01 → 2022-09-30¥81m
jpcrp040300-q3r_E24158-000Laboratory Consumable Equipmentreportable segmentsegment profit2022-01-01 → 2022-09-30−¥70m
—segment totalrevenue2022-01-01 → 2022-09-30¥88m
—segment totalrevenue external2022-01-01 → 2022-09-30¥88m
—segment totalsegment profit2022-01-01 → 2022-09-30−¥418m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 246
ItemContextValueUnit
Shareholders equityPrior1YearInstant_NonConsolidatedMember1020191000JPY
Shareholders equityCurrentQuarterInstant_NonConsolidatedMember1057079000JPY
Valuation difference on available for sale securitiesPrior1YearInstant_NonConsolidatedMember-321000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant_NonConsolidatedMember-321000JPY
Valuation and translation adjustmentsPrior1YearInstant_NonConsolidatedMember-321000JPY
Valuation and translation adjustmentsCurrentQuarterInstant_NonConsolidatedMember-321000JPY
Subscription rights to sharesPrior1YearInstant_NonConsolidatedMember24757000JPY
Subscription rights to sharesCurrentQuarterInstant_NonConsolidatedMember24851000JPY
Net assetsPrior1YearInstant_NonConsolidatedMember1044627000JPY
Net assetsCurrentQuarterInstant_NonConsolidatedMember1081609000JPY
Liabilities and net assetsPrior1YearInstant_NonConsolidatedMember1408209000JPY
Liabilities and net assetsCurrentQuarterInstant_NonConsolidatedMember1482490000JPY
Net salesCurrentYTDDuration_NonConsolidatedMember88185000JPY
Cost of salesCurrentYTDDuration_NonConsolidatedMember45405000JPY
Gross profitCurrentYTDDuration_NonConsolidatedMember42780000JPY
Research and development expenses sgaCurrentYTDDuration_NonConsolidatedMember333949000JPY
Other sgaCurrentYTDDuration_NonConsolidatedMember273300000JPY
Selling general and administrative expensesCurrentYTDDuration_NonConsolidatedMember607250000JPY
Operating incomeCurrentYTDDuration_NonConsolidatedMember-564470000JPY
Interest income noiCurrentYTDDuration_NonConsolidatedMember10000JPY
Foreign exchange gains noiCurrentYTDDuration_NonConsolidatedMember1993000JPY
Commission fee noiCurrentYTDDuration_NonConsolidatedMember175000JPY
Other noiCurrentYTDDuration_NonConsolidatedMember25000JPY
Non operating incomeCurrentYTDDuration_NonConsolidatedMember2204000JPY
Interest expenses noeCurrentYTDDuration_NonConsolidatedMember628000JPY
Stock issuance cost prior noeCurrentYTDDuration_NonConsolidatedMember7887000JPY
Non operating expensesCurrentYTDDuration_NonConsolidatedMember8515000JPY
Ordinary incomeCurrentYTDDuration_NonConsolidatedMember-570781000JPY
Gain on reversal of subscription rights to shares eiCurrentYTDDuration_NonConsolidatedMember2358000JPY
Extraordinary incomeCurrentYTDDuration_NonConsolidatedMember2358000JPY
Impairment loss elCurrentYTDDuration_NonConsolidatedMember3104000JPY
Extraordinary lossCurrentYTDDuration_NonConsolidatedMember3104000JPY
Income before income taxesCurrentYTDDuration_NonConsolidatedMember-571527000JPY
Income taxes currentCurrentYTDDuration_NonConsolidatedMember2850000JPY
Income taxesCurrentYTDDuration_NonConsolidatedMember2850000JPY
Profit lossCurrentYTDDuration_NonConsolidatedMember-574377000JPY
Revenues from external customersCurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q3r_E24158-000LaboratoryConsumableEquipmentReportableSegmentsMember81230000JPY
Revenues from external customersCurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q3r_E24158-000CellSheetRegenerativeMedicineReportableSegmentsMember6955000JPY
Revenues from external customersCurrentYTDDuration_NonConsolidatedMember_ReportableSegmentsMember88185000JPY
Revenues from external customersCurrentYTDDuration_NonConsolidatedMember_ReconcilingItemsMember－JPY
Revenues from external customersCurrentYTDDuration_NonConsolidatedMember88185000JPY
Transactions with other segmentsCurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q3r_E24158-000LaboratoryConsumableEquipmentReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q3r_E24158-000CellSheetRegenerativeMedicineReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_NonConsolidatedMember_ReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_NonConsolidatedMember_ReconcilingItemsMember－JPY
Transactions with other segmentsCurrentYTDDuration_NonConsolidatedMember－JPY
Net salesCurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q3r_E24158-000LaboratoryConsumableEquipmentReportableSegmentsMember81230000JPY
Net salesCurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q3r_E24158-000CellSheetRegenerativeMedicineReportableSegmentsMember6955000JPY
Net salesCurrentYTDDuration_NonConsolidatedMember_ReportableSegmentsMember88185000JPY
Net salesCurrentYTDDuration_NonConsolidatedMember_ReconcilingItemsMember－JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 9 of 9 passed
balance sheet identitynon_consolidated 2021-12-31pass rounding
balance sheet identitynon_consolidated 2022-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2021-12-31pass
statement vs summary · net assetsnon_consolidated 2022-09-30pass
statement vs summary · revenuenon_consolidated 2022-01-01/2022-09-30pass
statement vs summary · total assetsnon_consolidated 2021-12-31pass
statement vs summary · total assetsnon_consolidated 2022-09-30pass